Autoantibodies as predictive tools in systemic sclerosis.

Area of Science:

• Immunology
• Rheumatology
• Autoimmunity

Background:

• The precise role of autoantibodies in systemic sclerosis (SSc) pathogenesis is not fully understood.
• However, SSc-specific autoantibodies are recognized as significant indicators of disease prognosis and organ involvement.
• Over half of SSc patients possess anti-centromere, anti-topoisomerase, or anti-RNA polymerase III antibodies, typically exclusively.

Approach:

• This review examines the clinical significance of various SSc-associated autoantibodies.
• It highlights antibodies like anti-U3RNP and anti-Th/To, specific to scleroderma, and those found in overlap syndromes such as anti-Pm/Scl, anti-Ku, and anti-U1RNP.
• The study also notes that a subset of SSc patients (up to 11%) may be antinuclear antibody-negative.

Key Points:

• Specific autoantibody profiles correlate strongly with distinct clinical presentations and disease trajectories in SSc.
• Anti-centromere, anti-topoisomerase, and anti-RNA polymerase III antibodies are the most prevalent SSc-specific autoantibodies.
• Other autoantibodies, including anti-U3RNP, anti-Th/To, anti-Pm/Scl, anti-Ku, and anti-U1RNP, are also relevant for diagnosis and classification.

Conclusions:

• Autoantibodies are indispensable tools for assessing patients with systemic sclerosis.
• Their specificities provide crucial insights into disease behavior, aiding in personalized patient management and outcome prediction.